Short-rib thoracic dysplasia 14 with polydactyly
diseaseOn this page
Also known as SRTD14
Summary
Short-rib thoracic dysplasia 14 with polydactyly (MONDO:0014688) is a disease caused by KIAA0586 (GenCC Strong), with 2 cohort genes.
At a glance
- Causal gene: KIAA0586 (GenCC Strong)
- Cohort genes: 2
- ClinVar variants: 1,319
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | short-rib thoracic dysplasia 14 with polydactyly |
| Mondo ID | MONDO:0014688 |
| OMIM | 616546 |
| DOID | DOID:0110096 |
| UMLS | C4225286 |
| MedGen | 901479 |
| GARD | 0018467 |
| Is cancer (heuristic) | no |
Also known as: short-rib thoracic dysplasia 14 with polydactyly · SRTD14
Data availability: 1,319 ClinVar variants · 4 GenCC gene-disease records.
Disease family
Classification path: human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › autosomal recessive cerebellar ataxia › autosomal recessive congenital cerebellar ataxia › Joubert syndrome and related disorders › Joubert syndrome with Jeune asphyxiating thoracic dystrophy › short-rib thoracic dysplasia 14 with polydactyly
Related subtypes (1): Joubert syndrome 21
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
600 retrieved; paginated sample, class counts are floors:
356 uncertain significance, 171 likely benign, 27 pathogenic, 19 benign, 11 conflicting classifications of pathogenicity, 8 likely pathogenic, 4 benign/likely benign, 3 pathogenic/likely pathogenic, 1 not provided
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1458692 | NC_000014.8:g.(?58711639)(59014694_?)del | ARID4A | Pathogenic | criteria provided, single submitter |
| 1068589 | NM_001329943.3(KIAA0586):c.1466_1476del (p.Lys489fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1070138 | NM_001329943.3(KIAA0586):c.1935del (p.Val646fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1070838 | NM_001329943.3(KIAA0586):c.4495+3755del | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1072185 | NM_001329943.3(KIAA0586):c.1667dup (p.Arg557fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1073545 | NM_001329943.3(KIAA0586):c.1075_1076del (p.Lys359fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1175094 | NM_001329943.3(KIAA0586):c.2536del (p.Val846fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1175854 | NM_001329943.3(KIAA0586):c.38del (p.Lys13fs) | KIAA0586 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1350774 | NM_001329943.3(KIAA0586):c.25G>T (p.Glu9Ter) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1357141 | NM_001329943.3(KIAA0586):c.4456C>T (p.Gln1486Ter) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1359882 | NM_001329943.3(KIAA0586):c.622dup (p.Thr208fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1369714 | NM_001329943.3(KIAA0586):c.3353del (p.Pro1118fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1379251 | NM_001329943.3(KIAA0586):c.126T>A (p.Cys42Ter) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1406363 | NM_001329943.3(KIAA0586):c.2050C>T (p.Arg684Ter) | KIAA0586 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1429932 | NM_001329943.3(KIAA0586):c.3700del (p.Val1234fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1435532 | NM_001329943.3(KIAA0586):c.1872del (p.Glu625fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1435732 | NM_001329943.3(KIAA0586):c.411-1371G>A | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1452576 | NM_001329943.3(KIAA0586):c.3638del (p.Pro1213fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1453326 | NM_001329943.3(KIAA0586):c.938del (p.Tyr313fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1453478 | NM_001329943.3(KIAA0586):c.4495+3777del | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1453784 | NM_001329943.3(KIAA0586):c.4225del (p.Glu1409fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1453816 | NM_001329943.3(KIAA0586):c.4495+3785A>T | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1456969 | NM_001329943.3(KIAA0586):c.3580C>T (p.Gln1194Ter) | KIAA0586 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1457512 | NM_001329943.3(KIAA0586):c.4495+3767A>T | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1457530 | NM_001329943.3(KIAA0586):c.2047_2048del (p.Glu683fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1457538 | NM_001329943.3(KIAA0586):c.1093del (p.Glu365fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1517797 | NM_001329943.3(KIAA0586):c.3142_3144+5del | KIAA0586 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1683813 | NM_001329943.3(KIAA0586):c.3097dup (p.Ala1033fs) | KIAA0586 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1899465 | NM_001329943.3(KIAA0586):c.653_663del (p.Asp218fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
| 1938645 | NM_001329943.3(KIAA0586):c.3718_3719del (p.Leu1240fs) | KIAA0586 | Pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 10 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| KIAA0586 | Strong | Autosomal recessive | short-rib thoracic dysplasia 14 with polydactyly | 10 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| KIAA0586 | Orphanet:397715 | Joubert syndrome with Jeune asphyxiating thoracic dystrophy |
| KIAA0586 | Orphanet:475 | Isolated Joubert syndrome |
Cohort genes → proteins
2 cohort genes, 2 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 2 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| KIAA0586 | HGNC:19960 | ENSG00000100578 | Q9BVV6 | Protein TALPID3 | gencc,clinvar |
| ARID4A | HGNC:9885 | ENSG00000032219 | P29374 | AT-rich interactive domain-containing protein 4A | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| KIAA0586 | Protein TALPID3 | Required for ciliogenesis and sonic hedgehog/SHH signaling. |
| ARID4A | AT-rich interactive domain-containing protein 4A | DNA-binding protein which modulates activity of several transcription factors including RB1 (retinoblastoma-associated protein) and AR (androgen receptor). |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 2 | 1.8× | 0.312 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| KIAA0586 | Other/Unknown | no | TALPID3 | |
| ARID4A | Other/Unknown | no | Chromo/chromo_shadow_dom, ARID_dom, Tudor |
Expression context
Cohort genes with no expression data: 0.
2 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 2 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| left testis | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| right testis | 1 |
| buccal mucosa cell | 1 |
| calcaneal tendon | 1 |
| sural nerve | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| KIAA0586 | 247 | ubiquitous | marker | male germ line stem cell (sensu Vertebrata) in testis, right testis, left testis |
| ARID4A | 277 | ubiquitous | marker | calcaneal tendon, sural nerve, buccal mucosa cell |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| ARID4A | 3,311 |
| KIAA0586 | 1,405 |
Structural data
PDB: 1 · AlphaFold-only: 1 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| ARID4A | P29374 | 7 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| KIAA0586 | Q9BVV6 | 47.61 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 8. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| HDACs deacetylate histones | 1 | 120.2× | 0.028 | ARID4A |
| Potential therapeutics for SARS | 1 | 114.2× | 0.028 | ARID4A |
| Chromatin organization | 1 | 81.6× | 0.028 | ARID4A |
| Chromatin modifying enzymes | 1 | 72.3× | 0.028 | ARID4A |
| SARS-CoV Infections | 1 | 55.4× | 0.029 | ARID4A |
| Viral Infection Pathways | 1 | 30.8× | 0.043 | ARID4A |
| Infectious disease | 1 | 24.8× | 0.046 | ARID4A |
| Disease | 1 | 13.1× | 0.076 | ARID4A |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| establishment of Sertoli cell barrier | 1 | 1685.2× | 0.007 | ARID4A |
| regulation of establishment of protein localization | 1 | 1203.7× | 0.007 | KIAA0586 |
| genomic imprinting | 1 | 495.6× | 0.010 | ARID4A |
| negative regulation of stem cell population maintenance | 1 | 383.0× | 0.010 | ARID4A |
| erythrocyte development | 1 | 263.3× | 0.012 | ARID4A |
| positive regulation of stem cell population maintenance | 1 | 172.0× | 0.015 | ARID4A |
| smoothened signaling pathway | 1 | 90.6× | 0.023 | KIAA0586 |
| negative regulation of transforming growth factor beta receptor signaling pathway | 1 | 86.9× | 0.023 | ARID4A |
| negative regulation of cell migration | 1 | 55.8× | 0.032 | ARID4A |
| cilium assembly | 1 | 36.8× | 0.041 | KIAA0586 |
| transcription by RNA polymerase II | 1 | 35.3× | 0.041 | ARID4A |
| spermatogenesis | 1 | 17.6× | 0.075 | ARID4A |
| negative regulation of DNA-templated transcription | 1 | 15.8× | 0.077 | ARID4A |
| negative regulation of transcription by RNA polymerase II | 1 | 8.9× | 0.125 | ARID4A |
| positive regulation of transcription by RNA polymerase II | 1 | 7.4× | 0.139 | ARID4A |
| regulation of transcription by RNA polymerase II | 1 | 5.8× | 0.164 | ARID4A |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2
Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| KIAA0586 | 0 | 0 |
| ARID4A | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| ARID4A | 5 | Binding:5 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | KIAA0586, ARID4A |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| KIAA0586 | 0 | — |
| ARID4A | 5 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.